Artificial Cartilage Tissue Using TGF-β Growth Factors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for regenerating articular cartilage face challenges such as poor mechanical strength, scaffold-related complications, and safety concerns with the use of exogenous materials and heterologous proteins, limiting the effectiveness and durability of artificial cartilage tissues.
Innovation Solution
The development of an artificial cartilage tissue cultured using mammalian cartilage-derived cells and serum or plasma from the same species, with the inclusion of transforming growth factor-β (TGF-β) superfamily growth factors, which results in a tissue with low water retention, high collagen and proteoglycan content, and enhanced biocompatibility and mechanical strength.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If myeloid cells are introduced from bone marrow to form cartilage, then cartilage regeneration is achieved, but the regenerated cartilage has poor mechanical strength and joint function lasts only for several years
Solution Approach 1:
The patent changes the cellular parameters by using cartilage-derived cells instead of myeloid cells, and modifies the extracellular matrix composition by incorporating TGF-β superfamily growth factors to enhance collagen and proteoglycan production, resulting in cartilage with improved mechanical strength and durability
Solution Approach 2:
The patent creates a composite structure combining cartilage-derived cells with a customized extracellular matrix containing TGF-β superfamily growth factors, producing an artificial cartilage tissue that exhibits both regenerative capability and enhanced mechanical strength
2Strength
If exogenous scaffolds are used for cartilage repair, then structural support is provided, but scaffold-related complications and safety concerns arise
Solution Approach 1:
The patent extracts and eliminates the need for exogenous scaffolds by utilizing the patient's own cartilage-derived cells to produce a self-contained artificial cartilage tissue, thereby removing scaffold-related complications and safety concerns while maintaining structural support through the naturally produced extracellular matrix
Solution Approach 2:
The patent enables the cartilage-derived cells to self-organize and produce their own extracellular matrix with TGF-β superfamily growth factors, creating a self-sufficient artificial cartilage tissue that does not require external scaffold support and eliminates associated safety risks
3Productivity
If heterologous proteins are used in cartilage tissue, then tissue growth is promoted, but safety risks increase
Solution Approach 1:
The patent changes the protein source parameter from heterologous to autologous by using TGF-β superfamily growth factors derived from the same species as the cartilage-derived cells, maintaining tissue growth promotion while eliminating safety risks associated with heterologous proteins
4Object-affected harmful factors
If artificial joint replacement is performed, then acute pains are relieved, but joint function is largely limited and life span is about 15 years
Solution Approach 1:
The patent replaces the temporary artificial joint replacement with a biocompatible artificial cartilage tissue that integrates with the patient's natural cartilage, providing a longer-lasting solution that maintains joint function without the 15-year limitation of artificial joints
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach produces artificial cartilage with superior engraftability and mechanical strength, eliminating the need for exogenous scaffolds and reducing safety risks, enabling effective cartilage repair with improved durability and integration.
Implementation Method 1
cultured using mammalian cartilage-derived cells and serum or plasma from the same species, with the inclusion of transforming growth factor-β (TGF-β) superfamily growth factors, which results in a tissue with low water retention, high collagen and proteoglycan content
Implementation Method 2
with the inclusion of transforming growth factor-β (TGF-β) superfamily growth factors, which results in a tissue with low water retention, high collagen and proteoglycan content, and enhanced biocompatibility and mechanical strength
Implementation Method 3
superior engraftability and mechanical strength, eliminating the need for exogenous scaffolds and reducing safety risks, enabling effective cartilage repair with improved durability and integration
Data Source
AI summary
To obtain an artificial cartilage tissue having high strength and biocompatibility. There is provided an artificial cartilage tissue which is substantially free of heterologous protein and is substantially free of scaffold derived from non-cartilage-derived cells, but contains mammalian cartilage-derived cells and an extracellular matrix formed by the cartilage-derived cells, where: (1) the water retention per mg of tissue dry weight is 17.8 mg or less; (2) collagen of 5.57 μg or more per mg of tissue wet weight is contained; (3) proteoglycan of 9.22 μg or more per mg of tissue wet weight is contained.